NEFL and Creutzfeldt Jacob disease: Unfortunately, the retrospective study design did not allow comparative evaluations with ELISA 14-3-3, beta-amyloid 1–42, or recent biomarker candidates for CJD such as neurofilament light chain, alpha-synuclein, or soluble triggering receptor expressed on myeloid cells 2 (TREM2).